We collect cookies for vital website function and to better serve our customers. By continuing to browse you agree to the storing of cookies on your device. See our privacy policy for details.

AZD 6244

Item № 11599
CAS № 606143-52-6
Purity ≥95%
product image
                (CAS 606143-52-6)
SIZE PRICE QUANTITY SUBTOTAL
CART TOTAL
     10 mg $49.00 0.00
     25 mg $61.00 0.00
     50 mg $86.00 0.00
     100 mg $123.00 0.00

Pricing updated 2019-07-23. Prices are subject to change without notice.

Description
Synonyms
  • ARRY-142886
  • CL 1,040
  • NSC 741O78
  • Selumetinib

MEK kinases are central components of diverse intracellular signaling pathways. MEK1 and MEK2 specifically act downstream of growth factor receptors and the proto-oncogenes Ras and Raf to activate ERK1 and ERK2, often leading to an increase in cell proliferation.1 AZD 6244 is a potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14 and 530 nM, respectively).2,3,1 It weakly inhibits the EGF receptor (IC50 = 7.0 µM) and has no effect on a large panel of other kinases.2 AZD 6244 suppresses the growth of tumors displaying high levels of phosphorylated MEK1/2 or ERK1/2.3,1 In addition to suppressing growth, it induces apoptosis and differentiation within tumors.4 AZD 6244 has potential, alone or in combination therapy, for promoting tumor regression in various forms of cancer, including those involving mutations of the proto-oncogenes Ras and Raf.5,6

Recommended Products

Related Products
View Related Product Categories
Technical Information
Formal Name
5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
CAS Number
606143-52-6
Synonyms
  • ARRY-142886
  • CL 1,040
  • NSC 741O78
  • Selumetinib
Molecular Formula
C17H15BrClFN4O3
Formula Weight
457.7
Purity
≥95%
Formulation
A crystalline solid
λmax
214, 258 nm
SMILES
CN(C=N1)C2=C1C(F)=C(NC3=CC=C(Br)C=C3Cl)C(C(NOCCO)=O)=C2
InChI Code
InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChI Key
CYOHGALHFOKKQC-UHFFFAOYSA-N

Warning - this product is not for human or veterinary use.

Shipping & Storage
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Stability
≥ 2 years
Downloads & Resources
Product Downloads

Download Product Insert

Download Safety Data Sheet (SDS)

Download free InChI Key generation software

Additional Information

View the Cayman Structure Database for chemical structure definitions for many Cayman products

Get Batch-Specific Data and Documents by Batch Number

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.

References & Product Citations
Product Description References

1. Yeh, T.C., Marsh, V., Bernat, B.A., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase ½ inhibitor Clinical Cancer Research 13(5), 1576-1583 (2007).

2. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity Nat.Biotechnol. 29(11), 1046-1051 (2011).

3. Huynh, H., Soo, K.C., Chow, P.K.H., et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma Molecular Cancer Therapeutics 6(1), 138-146 (2007).

4. Davies, B.R., Logie, A., McKay, J.S., et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase ½ kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Molecular Cancer Therapeutics 6(8), 2209-2219 (2007).

5. Corcoran, R.B., Cheng, K.A., Hata, A.N., et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23(1), 121-128 (2013).

6. Robert, C., Dummer, R., Gutzmer, R., et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study Lancet Oncol. 14(8), 733-740 (2013).

Technical Support
Contact Us
  • Toll Free Phone (USA and Canada Only): (888) 526-5351
  • Direct Phone: (734) 975-3888
Cayman Contract Services

We work with scientists to accelerate their research, drug discovery, and drug development needs through our expertise in the following areas:

Cayman Chemical

1180 East Ellsworth Road

Ann Arbor, Michigan 48108 USA

Toll Free: (800) 364-9897

(USA and Canada Only)

Fax: (734) 971-3640